Captrust Financial Advisors Veracyte, Inc. Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$15.45 - $29.52 $40,061 - $76,545	-2,593 Reduced 80.55%	626 $12,000
Q2 2022 Aug 16, 2022	BUY	$15.45 - $29.52 $43,615 - $83,334	2,823 Added 712.88%	3,219 $64,000
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $4,212 - $8,161	192 Added 94.12%	396 $11,000
Q4 2021 Feb 14, 2022	SELL	$36.09 - $53.79 $4,005 - $5,970	-111 Reduced 35.24%	204 $8,000
Q3 2021 Nov 16, 2021	BUY	$35.62 - $52.97 $3,775 - $5,614	106 Added 50.72%	315 $15,000
Q2 2021 Aug 16, 2021	SELL	$32.94 - $56.62 $2,898 - $4,982	-88 Reduced 29.63%	209 $8,000
Q1 2021 May 17, 2021	BUY	$44.47 - $81.38 $13,207 - $24,169	297 New	297 $16,000

311

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.9B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.